References
- American College of Radiology. CT/MRI Liver Imaging Reporting and Data System version 2018. Acr.org Web site. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018. Accessed August 12, 2018
- Gervais DA. LI-RADS treatment response algorithm: performance and diagnostic accuracy. Radiology 2019;292:235-236 https://doi.org/10.1148/radiol.2019190768
- Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-750 https://doi.org/10.1002/hep.29913
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236 https://doi.org/10.1016/j.jhep.2018.03.019
- Kim HC. Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2017;23:109-114 https://doi.org/10.3350/cmh.2017.0004
- Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012;56:464-473 https://doi.org/10.1016/j.jhep.2011.07.012
- Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, et al. Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives. World J Gastroenterol 2015;21:6518-6525 https://doi.org/10.3748/wjg.v21.i21.6518
- Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81 https://doi.org/10.1002/hep.21980
- Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741-1749 https://doi.org/10.1002/hep.23944
- Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64 https://doi.org/10.1053/j.gastro.2009.09.006
- Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868-878 https://doi.org/10.1002/hep.24451
- Shropshire EL, Chaudhry M, Miller CM, Allen BC, Bozdogan E, Cardona DM, et al. LI-RADS treatment response algorithm: performance and diagnostic accuracy. Radiology 2019;292:226-234 https://doi.org/10.1148/radiol.2019182135
- Chaudhry M, McGinty KA, Mervak B, Lerebours R, Li C, Shropshire E, et al. The LI-RADS version 2018 MRI treatment response algorithm: evaluation of ablated hepatocellular carcinoma. Radiology 2020;294:320-326 https://doi.org/10.1148/radiol.2019191581
- Seo N, Kim MS, Park MS, Choi JY, Do RKG, Han K, et al. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017. Eur Radiol 2020;30:261-271 https://doi.org/10.1007/s00330-019-06376-5
- Cools KS, Moon AM, Burke LMB, McGinty KA, Strassle PD, Gerber DA. Validation of the liver imaging reporting and data system treatment response criteria after thermal ablation for hepatocellular carcinoma. Liver Transpl 2020;26:203-214 https://doi.org/10.1002/lt.25673
- Kim SW, Joo I, Kim HC, Ahn SJ, Kang HJ, Jeon SK, et al. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 2020;30:2861-2870 https://doi.org/10.1007/s00330-019-06623-9
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174 https://doi.org/10.2307/2529310
- Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:532-540 https://doi.org/10.1007/s00270-009-9728-y
- Amorim J, Franca M, Perez-Girbes A, Torregrosa A, Marti-Bonmati L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol (NY) 2020;45:3119-3128 https://doi.org/10.1007/s00261-020-02470-1
- Semaan S, Makkar J, Lewis S, Chatterji M, Kim E, Taouli B. Imaging of hepatocellular carcinoma response after 90Y radioembolization. AJR Am J Roentgenol 2017;209:W263-W276 https://doi.org/10.2214/AJR.17.17993
- Min JH, Kang TW, Kim YY, Cha DI, Kim YK, Kim SH, et al. Vanishing washout of hepatocellular carcinoma according to the presence of hepatic steatosis: diagnostic performance of CT and MRI. Eur Radiol 2020 Nov [Epub]. https://doi.org/10.1007/s00330-020-07438-9
- Kim DH, Choi SH, Byun JH, Kang JH, Lim YS, Lee SJ, et al. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. J Hepatol 2019;71:534-542 https://doi.org/10.1016/j.jhep.2019.05.005